Novavax, Inc. (NASDAQ:NVAX) announced it will utilize the accelerated approval pathway for licensure for NanoFlu™, its nanoparticle seasonal influenza vaccine candidate. The U.S. Food and Drug Administration (FDA) acknowledged in a recent letter that the accelerated approval pathway is available to Novavax for its NanoFlu vaccine. Novavax expects to initiate its pivotal Phase 3 clinical trial by the fall of 2019 with top-line clinical data expected in the first quarter of 2020. These immunogenicity data are expected to support a U.S. biologics license application (BLA).
Technical Stock Analysis
Novavax, Inc. (NASDAQ:NVAX), a Healthcare sector firm, traded 509396 shares in last trading session and stock shed -1.42% with closing price of $5.54 per share. Company gross margins represents its total sales revenue minus its cost of goods sold (COGS), divided by the total sales revenue earned by the company, expressed as a percentage. And its good to know that the higher that percentage, the more the company retains on each dollar of sales, to service its other costs and the debt obligations.
Investment Worthy Stock or not?
For personal guess ROI is usually expressed as a percentage and is typically used for taking any financial decisions, for the purpose of comparing a Novavax, Inc. (NASDAQ:NVAX)’s profitability or to compare the efficiency of different investments.
52-Week Range
52-Week Range are valuable stats for watching Novavax, Inc. (NASDAQ:NVAX)’s past year fluctuation as that gives investors an idea of how much the security has moved in the last year and whether it is trading near the top, middle or bottom of the range. Novavax, Inc. (NASDAQ:NVAX)’s stock value has moved between $4.66 – 50.36 in last one year.
Analyst’s Views
Analysts mean target price for Novavax, Inc. (NASDAQ:NVAX) is $24.71 while analysts mean recommendation is 2.10.
Stock Performance
Its weekly performance is 7.78% while year to date (YTD) performance is -84.95%.
EPS Growth
Earnings per share growth is defined as the percentage change in normalised earnings per share over the previous 12 month period to the latest year end. It gives a good picture of the rate at which a company has grown its profitability. Novavax, Inc. (NASDAQ:NVAX)’s EPS growth this year is 20.40%. For best decision making investors should look at Novavax, Inc. (NASDAQ:NVAX)’s EPS growth for next year stands at 19.10%.
